Once TSH could be radiolabeled without losing its biological activity, it became possible to rapidly detect such stimulating activity in sera from patients with Graves’ disease since the antibody had been shown to be an immunoglobulin (IgG) which would compete with TSH for binding to the TSHR. This evidence concerns the gene TSHR and Graves disease.